SpaceX Rallies For Third Straight Day, Becoming World's Fifth Largest Stock

16 Jun 2026 · 35 min · 15 chapters

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

The episode of Bloomberg Businessweek Daily covers three market themes: SpaceX’s public-market debut and the trading mechanics around its IPO, the financialization of GPUs used for AI, and AI-driven growth in healthcare/medtech.

Guests and backgrounds

Bailey Lipschultz, Bloomberg News IPO reporter; Simon White, Bloomberg Macro Strategist (London); Mike Dinsdale, CEO/co-founder of PowerLaw (venture-backed closed-end fund); David Roman, U.S. MedTech and healthcare IT research analyst at Goldman Sachs; Madison Muller, Bloomberg News U.S. healthcare reporter.

Key claims

SpaceX’s stock swings reflect options/ETF flows and “Elon dream” valuation uncertainty; GPU-backed debt could resemble early mortgage securitization, with fast GPU depreciation and obsolescence risk; healthcare AI is already becoming a business via automation in diabetes management, arrhythmia triage, and robotic-surgery standardization.

Notable examples

SpaceX call/put options and levered ETFs; GPU-as-collateral deals like CoreWeave; Dexcom/Abbott carb-counting, iRhythm Zeopatch triage, Intuitive’s MyIntuitive Plus; PowerLaw holdings including SpaceX and OpenAI; discussion of closed-loop insulin therapy integration limits.

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Chapters

Tap a time to open that second in VO

Analyzing SpaceX's Stock Performance

1:00 to 1:30

Discussion on SpaceX's stock movements, market reactions, and investor behavior.

“When you own your own business, you own every decision.”

Analyzing SpaceX's Stock Performance

1:55 to 8:00

Discussion on SpaceX's stock movements, market reactions, and investor behavior.

“Reporting from the magazine that helps global leaders stay ahead.”

The Financialization of GPUs

8:00 to 14:00

Exploration of GPU financing and its implications for the economy and markets.

“They just closed down shop because they couldn't close their positions.”

Discussion on Technological Risks

14:00 to 14:50

Explore the risks of technological obsolescence and demand destruction in AI.

“got an extra risk, if you like, right, because, you know, you've got this, they can very quickly become technologically obsolescent, like a house.”

Introduction to PowerLaw Corporation

16:01 to 16:58

Overview of PowerLaw Corporation and its strategy for retail investors.

“But without identity, you can't trust they'll serve your business instead of jeopardizing it.”

Investing in Closed-End Funds

16:59 to 19:28

Insights on how PowerLaw aims to democratize access to private investments.

“The platform behind it is PowerLaw Capital Group.”

Analyzing Market Trends and Volatility

19:29 to 22:38

Discussion on the volatility of closed-end funds and the value of private investments.

“I guess I just wondered, like, how do you look upon that?”

The Future of PowerLaw's Portfolio

22:39 to 23:38

Insights into how PowerLaw plans to manage its portfolio as companies go public.

“We have potentially an IPO soon from Anthropic, another one from OpenAI, potentially more on the horizon.”

Challenges for SpaceX in Public Markets

23:39 to 28:09

Discuss the challenges SpaceX faces as it transitions to public markets.

“Now, Mike, just back on SpaceX, I mean, what did you think about the debut of SpaceX?”

Challenges Facing SpaceX's Public Transition

28:09 to 29:24

Discussion on the challenges SpaceX faces as it transitions to the public markets.

“And in our case, we've done almost 900 secondary transactions.”
Show all 15 chapters

Challenges Facing SpaceX's Public Transition

29:25 to 30:47

Discussion on the challenges SpaceX faces as it transitions to the public markets.

“More from Bloomberg Businessweek Daily coming up after this.”

Healthcare Innovations from Goldman Sachs

30:58 to 32:06

Insights into recent innovations in healthcare technology discussed by experts.

“Advisory services by Public Advisors, SEC Registered Advisor, crypto services by ZeroHash.”

Healthcare Innovations from Goldman Sachs

32:10 to 38:03

Insights into recent innovations in healthcare technology discussed by experts.

“Cards are issued by JPMorgan Chase Bank N.A., member FDIC.”

Continuous Glucose Monitors and Consumer Market

38:03 to 40:14

Exploration of the consumer market potential for continuous glucose monitors.

“I'm shocked, actually, at how fast it's gone.”

Maximizing Team Productivity

42:00 to 42:26

Learn how focusing on the right tasks can enhance productivity.

“Ask yourself, what are your best people spending their time on right now?”
Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:00What if data didn't sit still? What if intelligence moved with us? Not buried in reports, but activated in real time, where lives are being shaped, where decisions are being made. It all starts with a question. Where is the potential? Cotality turns data into clarity, intelligence into insight, insight into action. Because when intelligence moves, we all move forward. Cotality. Intelligence beyond bounds. The thing about AI for business, it may not automatically fit the way your business works. At IBM, we've seen this firsthand. But by embedding AI across HR, IT, and procurement processes, we've reduced costs by millions, slash repetitive tasks, and freed thousands of hours for strategic work.

0:50Now we're helping companies get smarter by putting AI where it actually pays off, deep in the work that moves the business. Let's create smarter business, IBM. When you own your own business, you own every decision. Now own the card that rewards you for it. Chase Sapphire Reserve for Business is a pay-in-full card that elevates your travel experience and offers premium benefits that will take your business to the next level. Sapphire Reserve for Business offers 8x points on all purchases through Chase Travel, 3x points on social media and search engine advertising, airport lounge access, and more.

1:25Chase Sapphire Reserve for Business. It's the card that gives back all you put in. Learn more at chase.com forward slash reserve business. Chase for business. Make more of what's yours. Accounts subject to credit approval. Restrictions and limitations apply. Cards are issued by JPMorgan Chase Bank N.A. Member FDIC. Bloomberg Audio Studios. Podcasts. Radio. News. This is Bloomberg Business Week Daily. Reporting from the magazine that helps global leaders stay ahead. with insight on the people, companies, and trends shaping today's complex economy, plus global business, finance, and tech news as it happens.

2:08The Bloomberg Businessweek Daily Podcast with Carol Masser and Tim Stenebeck on Bloomberg Radio. Bailey Lipschultz is Bloomberg News IPO reporter. I think a lot of people who have been tuning in over the last week might think he lives in midtown Manhattan at Bloomberg headquarters, but no, he's actually joining us from New Jersey today. he did get out of the office, which I'm glad he did. It looks like he's in the office. It does. That's the magic of television. The magic of the magic of a green screen. I don't know actually how to turn off the zoom just so it's clear. Any meeting I have, people were like, are you in an elevator?

2:43Are you Bloomberg? And I'm like, no, I'm doing something else. Well, no matter where you are, Bailey, we're glad you're with us. Sorry, go ahead on this valuation question because I'm beating this drum a lot. But I'm wondering who's buying shares in this company right now. Well, we're seeing kind of a mix of things, right? So today was the first day for call options, well, put options, but options writ large to be able to be purchased. So similar to what we saw with GameStop, to an extent, if people are buying and rushing to buy out of the money call options, that can artificially and in real life move the stock price higher, even though no one's actually buying the underlying stock from that perspective, because people have, market makers have to buy the stock.

3:22That's one thing to keep in mind. The second thing is we've seen volume slow down, but they're still quite high. So you have news of this cursor deal planning to close pretty much ASAP. This builds on yesterday being the first day with levered ETFs. So it's going to be interesting to me where the stock trades tomorrow because you obviously had the euphoria from Friday. You had all of the overseas investors who maybe weren't awake in their Saturday night, Saturday mornings to buy the stock on our Friday regular trading. So they lined up potentially Monday morning. So as we get to Wednesday, we get to a little bit more normalized, as it were, trading.

3:57But still, this is, again, a stock that can move quite a bit. Yeah, well, it's moving quite a bit today. It was up as much as 17 % earlier. It's now down. It's now up only four and a half percent. So it's moved a lot just today. Yeah, kind of telling. Right. I mean, there were so, as you say, you know, so much pent up demand, right, that people wanted a piece of it. But as the days go on, then we start to be like, OK, kind of show me the money. I don't know. Show me the earnings. Like, I don't know. What is it? Well, I think that's something we track with a number of stocks. Recon IPOs, this is kind of not a new phenomenon.

4:28It's definitely something we've seen in the last few years. Tim, just think back to when Sarah Bross went public. It pretty much shot out of the gates and came back a bit to earth and then kind of found its footing and found what the market was willing to pay for it. So that's what we've been seeing. And it's not necessarily a negative sign. It's certainly something we've been keeping a track of. When you look back to Circle, it's trading about where it closed day one, and that's T plus a number of months. So the big question going forward is you have the FTSE Russell buying on the near term horizon.

4:55You have that NASDAQ 100 buying early next month. So investors are positioning for that. What happens when they're adding to that and you do get the forced buying? And what happens when we're a month out from the IPO and you maybe don't have a catalyst? Well, maybe a catalyst is when we start to hear from banks initiating coverage, Bailey. When, you know, so many banks were involved in this. I know there are some restrictions on when they can initiate coverage. what do you look for from the analyst community? Well, that'll be the first few days on the other side of the 4th of July holiday, just so you can mark your calendars now.

5:30Wall Street will look at this and certainly buy the Elon dream, but I expect to see some skepticism just looking at Tesla, where again, it is probably the most debated stock, even from the sell side, people whose banks make money off of the company selling equity and selling debt and selling other instruments. But it's certainly gonna be, Tim, something we've never seen before, just because, I don't know, how do you model for the total addressable market of the moon? What does the asteroid mining opportunity look like to some of these analysts? I think that's going to be a thing to keep an eye on, in addition to the fact that, again, this is the company that's going to have to spend a lot of money to realize that dream.

6:06Well, there's total addressable market. I mean, anybody can throw a number out there, Bailey, but whether or not it can actually be done, we've talked so much about the Starship rocket, right, And how much is kind of weighing on that being successful in kind of supporting his, you know, action and plan and mission, no pun intended, to, you know, launch data centers in space? Like, there's a lot that has to happen. Oh, no doubt. And I think people who are willing to bet on Elon Musk, I hope, realize that. Again, if you look at Tesla's valuations, north of one and a half trillion dollars, smaller than SpaceX right now.

6:42But that's still predicated on Optimus being something we all live and use. It's also partly predicated on RoboTaxi being how people actually get to work instead of buying cars. And if you buy a car, you buy a Tesla and use their insurance. That has a lot of hopium built into it. And we're seeing that with SpaceX. Again, the downside for SpaceX fundamentally is space is very hard. Rockets are very hard. The upside is if you succeed, they're a decade ahead of the next closest competitor. So how large is that moat? And does it only grow? And again, we've seen we've never seen something like this in terms of the bulls and bears presumably taking their own sides.

7:18But anyone who's betting against the company has to look at the last three days and say, I actually don't know where this is going to go. Right. It's the bet against Elon, too. Right, Bailey? I mean, we talk about this all the time. I mean, how long have we covered him? How many questions have there been? How many timelines or deadlines did he miss? And yet he has really changed so much dramatically. If you think about space exploration, even EVs, we could question at this moment in time where there's been kind of a pushback because of policy. But you really changed the discussion around them.

7:52No, and I mean, again, the market can stay irrational longer than you can stay solvent. So eventually people are right. I mean, hey, a number of short sellers in January 2021 were right about GameStop. They just closed down shop because they couldn't close their positions. So it's certainly that's a big dynamic as well. Bailey dropping the quotes that are supposedly attributed to John Maynard Keynes. But who knows if they are? I love it. Bailey Lipschultz. You're listening to the Bloomberg Business Week Daily Podcast. Catch us live weekday afternoons from 2 to 5 Eastern. Listen on Apple CarPlay and Android Auto with the Bloomberg Business app.

8:31Or watch us live on YouTube. Well, in terms of what's moving markets over the last few months, war certainly has done that. Also at the center of it all is AI spend, especially when it comes to those semiconductors. Yeah, this goes to a story that really caught my attention on my morning read. And it was a macroscope column. It's written by Bloomberg Simon White. First line in the column, the financialization of GPUs is a nascent risk to the economy and market. So let's get to it. Simon's been kind enough to stick around in our London News Bureau over in Bloomberg. It's a little bit later there.

9:05He is Bloomberg Macro Strategist. Simon, thank you so much. I think drove my team crazy saying, I want to do the story this morning. I want to do the story. History doesn't repeat itself, but it often rhymes. And that is true, too, for financial markets. Walk us through your thinking when it comes to GPUs, what we're seeing, the spend, the build out, and what's going on in markets. Well, thanks for having me. So these are the latest innovation in finance, which, as you said, there is some early parallels, if you like, to what happened in the early days of the financial crisis. But essentially, we're talking about here, the centre of the new economy, the AI economy, is these GPUs.

9:46So they are much more expensive than CPUs. And that is the kind of architecture that AI needs to run on. And you need to build these vast data sensors, and these cost a lot of money to fund. So we have this new innovation, which is debt-backed by these GPUs. So, you know, the financial markets are doing what it's done before. It did it with mortgages in the years up to, you know, 2008, where it takes something that is essentially illiquid and untradeable and makes it liquid and tradable. So it's very early days. We've seen something in the region of maybe only a few billion of these deals over the last few years, but this year to date so far, there's already been$65 billion of these deals.

10:29So relatively small amount, but some of the deals are getting really big sized. So you've got neoclouds as they're called. So companies like CoreWeave that provide GPU as a service and they need to basically get funding to build these massive data centers. And the way they're trying to inveigle investors is to collateralize the debt with the GPUs. So they're basically, the GPUs they've got, they're basically collateralizing the debt. And this is, as I say, the aim to try and draw on investors and make them more comfortable with the risk that they're taking. Yeah. And this comes what, you know, we now have initial trading volume strong for NVIDIA's new bonds.

11:09Prices have remained near where the$25 billion worth of debt was sold at. This is something we talked about, these new seven-year notes. We talked about it yesterday, but it's trading today. Simon, you mentioned it worked with mortgage-backed securities up until the financial crisis, and we all saw what happened then. I don't want to say that that's going to happen again. We have no idea. But is that what happens in a cycle when these new products emerge? Well, there's a great quote from Jim Grant, I think said it, he said, progress in science is cumulative, and in markets and finance, it's cyclical.

11:46And so over time again, we see the same things happening over and over again. So 100%, I agree with you, it's very early days. But given where we've seen what Wall Street tends to do, it takes actually quite a good idea. And so it makes a lot of sense. financialise these very expensive assets. They're expensive to run. They have a lot of downtime. So that really makes the whole thing much more efficient. But unfortunately, Wall Street has a tendency not to be able to hold back. So we'll see again what actually happens here. But if you start to have a situation where you've got this debt-backed GPUs, GPUs-backed in this debt, as I say, we have a forward curve already.

12:26We're about to have a futures market in GPUs. That means you You can essentially short GPUs. That'll be on the cards lately. So, again, all the parallels that, you know, we took a mortgage. A mortgage used to sit on a bank's balance sheet. There's very little you could do about it. But then they started to package it into these MBS and then repackage them again into CDOs and all the other alphabet soup of things. And, you know, it's not impossible over the coming years that we see something similar happening to GPUs, just given the amounts of money involved. Hey, you know, when we think about asset backed securities, mortgages had homes, you know, declining in value, as we know.

13:01But having said that, GPUs, we often talk about this cycle where, you know, they get better, they get improved. People want to buy the newest, the latest. So those assets that are backing actually are declining in volume. Is that part of the problem? That's a very key point. Essentially, you've got assets that are kind of rotting, if you like, very fast. So the GPUs, I mean, Mike Burry, the famous short investor from The Big Short, ironically, in the housing crisis, did a big piece on depreciation of GPUs. And he is basically his idea is that a lot of the hyperscalers and people that hold vast amounts of the GPUs are not really accounting for their depreciation.

13:44depreciation. So it's a very controversial subject. But regardless, whether it's, you know, three to four years, they last or it's 78 years, they're very fast depreciating assets. So that means that you have to have these very aggressive pay down schedules on the loans. But then you've got an extra risk, if you like, right, because, you know, you've got this, they can very quickly become technologically obsolescent, like a house. It's very difficult to suddenly go, we've got a much better house. All the houses that exist already are obsolescent. Whereas obviously with chips, you know, that's not impossible.

14:16You know, someone comes up with a new way of using them. Or the other side of the thing is the demand. We've already seen some demand. I mean, your previous guest talking about Cursor, you know, pointed at token maxing, you know, already we're hitting some sort of demand destruction. So all these things really add to the risk new, but inherently very risky. All right. Good stuff. And something to certainly throw into the narrative as we continue to cover certainly the AI spend and AI build. Simon, again, thank you so much. Simon White, he is Bloomberg macro strategist joining us from our Bloomberg News London Bureau.

14:48Stay with us. More from Bloomberg Business Week Daily coming up after this.

14:56What if data didn't sit still? What if intelligence moved with us? Not buried in reports, but activated in real time, where lives are being shaped, where decisions are being made. It all starts with a question, where is the potential? Coatality turns data into clarity, intelligence into insight, insight into action. Because when intelligence moves, we all move forward. Coatality, intelligence beyond bounds. So there's a lot of noise about AI, but time's too tight for more promises. So let's talk about results. At IBM, we work with our employees to integrate technology right into the systems they need.

15:37Now, a global workforce of 300 ,000 can use AI to fill their HR questions, resolving 94 % of common questions. Not noise. Proof of how we can help companies get smarter by putting AI where it actually pays off. Deep in the work that moves the business. Let's create smarter business. IBM. These days, it seems like AI agents are just about everywhere you turn. every field and every function. But without identity, you can't trust they'll serve your business instead of jeopardizing it. Fortunately, Okta helps you get identity right by securing your AI agent's identities, giving you a single layer of control, a single standard of trust.

16:15So whether an AI agent supports a single user or your entire enterprise with Okta, you'll turn risk into opportunity. Secure every agent, secure any agent. Okta secures AI. You're listening to the Bloomberg Business Week Daily Podcast. Catch us live weekday afternoons from 2 to 5 p.m. Eastern. Listen on Apple CarPlay and Android Auto with the Bloomberg Business app. Or watch us live on YouTube. PowerLaw Corporation, it's a closed-end fund that owns stakes in Elon Musk's SpaceX and AI firm OpenAI. It recently began publicly trading. The fund coming to market, capitalizing really on retail investors' clamor for exposure to the hottest private tech companies they all want in.

16:56We all want it. Do we? I don't know. Maybe not. The platform behind it is PowerLaw Capital Group. It's backed by Adcadian Ventures, a San Francisco-based venture secondary firm,$1.36 billion in assets under management. We've got a great voice here to tell us more. Mike Dinsdale, CEO and co-founder at PowerLaw. He's former CFO of DocuSign, DoorDash, Gusto. He joins us from San Francisco. Also with us, the Bloomberg reporter who brought PowerLaw to our attention, Anthony Hughes, Bloomberg News, U.S. equity capital markets reporter. He joins us here in the studio. All right. Welcome, gentlemen. Good to have you here.

17:30Mike, let's kick it off. Tell us about PowerLaw, why the recent move to go public. And I am curious, like, why better to invest in a closed-end fund versus, let's say, now investing in SpaceX, now that retail investors, everybody, can get exposure that way? Well, first off, thank you very much for having me. And to just play off the first part when you opened up, the answer is yes, I do think everybody wants to own PowerLaw. So we are the first venture-backed firm to list a closed-end fund. And to answer your question around why not just buy SpaceX, I think people should buy SpaceX. I think it's a phenomenal company and will continue to grow for decades.

18:07But what we offer is other names as well. You mentioned OpenAI. There's names like CalSheet, Databricks, Kraken. And so our thesis has been that we want to provide a product that resonates with the$25 trillion in U.S. retirement accounts that have been locked out of access to privates. and the massive wealth creation that's been happening in private companies, we want to unlock that for everyone. Mike, traditionally, when it comes to those companies that you mentioned, venture capitalists obviously have access to those and the investors who invest in those venture capital firms. Also, wealthy individuals who may be accredited investors, perhaps they have access through their wealth managers to like a, you know, allocation of alternatives that include secondaries or investments in some of those venture firms.

18:53Do investors in power law have to be accredited investors or can anyone buy into this? No, I mean, that's really what we were trying to solve for, that you're talking about the accredited set. But when you look at the U.S. population, and it's even more globally, about 90 percent of U.S. households are cut out of access to private companies because they're not accredited. So they don't meet that wealth threshold. And our vision long term is to build products that allow anybody to invest no matter what their net worth no matter what their portfolio size is but to be built into their retirement savings and into those plans and give access to private companies this is our first fund we get we're going to continue to launch uh subsequent funds to give access to different pockets of technology but always focused on giving access to private companies something that we've been building a firm for 16 years to gain access and we think that it should open up to all.

19:46Yes, Mike, it's Anthony here. I think one of the interesting things about the closed-end funds, and it's not just your fund, there's been several others that have listed recently and there's been a few around for a few years, but the trading has been quite volatile, I think, around the SpaceX IPO, and I think your fund and others have traded at pretty big premiums or premium to the underlying value of the assets. I guess I just wondered, like, how do you look upon that? How do you explain those big premiums? And I think that's a fair degree of volatility as well. Yeah, I mean, there are a couple of other competitors.

20:18And when I look at our competitors, you know, our differentiation is we're venture capitalists. We've been investing in technology companies. I've been the CFO of some that you mentioned. We're different in that we're not just looking at the obvious names, which are the big names that we're all talking about, but what's next as well. And so how do we build portfolios that gives access to the companies that are going to be the big megas over the next five years or 10 years? And so we're focused on that and making sure that our portfolios are balanced. Our competitors in sort of our estimation are we have respect for all, but we're the we're the first institutional venture backed group to do this.

20:52And we think that gives us a real advantage. And, Mike, I think perhaps around 100, 200 million dollars of your portfolio is actually in SpaceX. I mean, now that the company's public, what's your intentions for that that that holding? Yeah, I mean, ultimately, our value to our shareholders is to provide access to private companies. So as the lockup comes off, and we have an opportunity to liquidate that position, we will do so as long as it benefits our shareholders. But ultimately, our goal is to reinvest the capital into more private companies, because that's the value we provide to our shareholders.

21:23And what do you how do you define beneficial to your shareholders? Because a lot can happen between now and when the lockup periods expire. Sure. I mean, I think you start off by saying everyone can own SpaceX and certainly they can buy it now in the open market. And so at some point, just the value we're providing goes away. So, yes, we're providing a balanced portfolio of other names, but the actual value prop that we have as a firm goes away as we're holding public equities. And so as companies in our portfolio go public, we will look to sell them down over time so we can reinvest and have what we believe will be bigger returns from private companies that they may have heard of or may not.

21:59But at the end of the day, our goal is to build a portfolio that increases in value and gives access to private companies, something that we're uniquely positioned to do here in San Francisco. But, Mike, if SpaceX continues to soar, will you be if it's in the benefit of your shareholders to hold on to it? Would you or your investors, would you hold on to it? I mean, the answer is absolutely yes, we can. We can hold public equities. And so we would we would assess that. And if we think that it makes the most sense and it's the best gain, then we would do that. But at the same time, I do think, again, our value is to give access to privates.

22:32And so we always look to that first and then make the right decision based on where we think the value is long term. So Cursor is getting bought by SpaceX. We have potentially an IPO soon from Anthropic, another one from OpenAI, potentially more on the horizon. And is the pipeline after all of these IPOs and acquisitions strong enough to maintain a solid portfolio of private assets? Oh, absolutely. I mean, I think that we all focus on the big megas, which really are the three you just mentioned, SpaceX, OpenAI, and Anthropic. But think about companies like Databricks and Stripe and some of these others that really are hundreds of billions of dollars in market cap today.

23:12They will eventually go public. And then when you get down below that, I mean, there's hundreds of companies that we're looking at and tracking and considering for our portfolio. And Power Law, to be clear, is what we believe best of the best big tech. And our thesis is around concentration. And so our goal is to have 15 names only in that portfolio. But as we launch subsequent products, we'll focus those on other areas that we think matter, like AI, defense, space, things like this, that are starting to emerge. And there's the next batch of those companies coming that we're tracking, and we'll add those to future funds.

23:45Now, Mike, just back on SpaceX, I mean, what did you think about the debut of SpaceX? Were you surprised about how well it's gone? I mean, it really has, after a really large valuation increase in private markets, it's also managed to attract a big valuation in public markets as well, a higher valuation. I mean, were you surprised by that? I'm really not. I mean, I've been a big believer in SpaceX for a decade. And I think that Starlink and the unlock that provides to communications globally is really underestimated. I mean, it really is a stair step and SpaceX as a company is a one of one. So I think it went as well as I expected and I think it will continue to go up.

Read the full transcript

24:21And it is something that I think people should hold for 10 years. And I think it makes sense. You know, I intend to myself. How important was it for your company, PowerLaw, to actually list prior to the SpaceX IPO? Was that strategic in terms of the timing? It was certainly something we were focused on because it made sense for us to list before spacex and they kept bringing in their ipo which was which was challenging for us but yeah it made sense and i mean again like our value prop is to provide access to those companies before they're public and so we were working hard to make sure that we did go public or list before they they they went public mike you mentioned some of the other companies in the portfolio i'll go through them again databricks stripe deal kalshi kraken tether perplexity canva ripplings uh figma waymo among others.

25:08How does a new company get into the portfolio? What are the rules that exist in an environment where I think a lot of people would argue there's not a lot of transparency? Yeah. Again, our heritage is a venture firm. And so we have a robust underwriting process, and we're very disciplined about how we evaluate companies. And we try and build a portfolio that has the big megas, which we've talked about, but then also has companies that perhaps people have not heard about, like companies like Sironic or Colossal Bioscience, which you didn't mention, that are doing really interesting things. And so we're always evaluating to have a balance across the big megas, which I think are somewhat obvious, and then going down into the what's next, what's coming up, and making sure we have a portfolio that has companies in it across those different stages, because I think that's where you get outsized returns.

26:00And Mike, I think I mentioned before that a lot of the closed-end funds, including yours, are trading at a premium to their assets. I mean, do you feel like the closed-end fund sector, as it were, could be, would be able to be, would, does plan to raise further capital in the future? Do you think that'll be something that a lot of closed-end funds will do? I mean, 100 % I do. I think there's a structural shift happening with venture overall. And I think we're going to see a lot more of these closed-end fund type structures as we head towards embedding them structurally in retirement accounts and eventually into 401k.

26:33So there's just no question there's benefits to invest in privates through this model. Even as an accredited investor, it makes sense to invest in models like PowerLaw because once we're trading, now you have full liquidity versus in venture. If you look at the trends, we have half the number of public companies that we did 25 years ago. Companies are obviously getting much, much, much larger. We have three essentially that are trillion dollar companies and still private. And so you want to have access and have part of your portfolio in those privates, but having built-in liquidity in the public markets makes sense.

27:03In terms of the premium, that's just straight supply demand. There's a massive amount of demand for these names, and we have very limited supply, and that will change over time. Our goal is to have a fund where investors make money. So we don't want a massively volatile fund. We don't want our stock price going up and down. We want to continue to put up returns for our investors over time and have a stock that investors can own for a decade. Yes, and Mike, a lot of your holdings are via special purpose vehicles, and I think Bloomberg has actually written quite a few articles about some of the issues in that area and some concerns about the transparency in fees associated with those sorts of structures.

27:46How much of an issue has that been? We haven't heard a lot about this issue since SpaceX went public, but is there something to play out there? I mean, I think it is. And I think that the press around this and things that Bloomberg's done make a lot of sense to make sure that non-professional investors that don't necessarily have the same underwriting capabilities don't go into vehicles that they don't understand. And in our case, we've done almost 900 secondary transactions. We're comfortable with all types of transaction SPVs. We are certainly in SPVs. About half of our deals are in SPVs in the Power Law Fund.

28:21But we follow through. We only have SPVs that are audited. We follow the trail through to the cap table. And so our underwriting process protects us. I think all the warnings we're seeing from companies and articles that are out there are all around protecting investors that are not professionals, that are not sophisticated, that don't have an underwriting process that's robust like ours. Hey, Mike, one last question. Just got about 30 seconds. You've been CFO of a bunch of large publicly held tech companies, including DocuSign. What do you see as the biggest challenges facing SpaceX as it transitions to the public markets just really quickly?

28:54Yeah, no, I think for SpaceX, it's bringing together the different companies. So bringing XAI in, obviously X is in there as well. And then just the different businesses and making sure there's focus across on those to expand SpaceX overall. But again, I think it's an asset that's a one-of-one, and I think it's a phenomenal company. All right, good stuff. Stay in touch. Mike Dinsdell, he's CEO and co-founder at Power Law. And our thanks to our Anthony Hughes, Bloomberg News, US ECM equity capital markets reporter, who brought us this story. And it's why we're out here talking to Mike. Stay with us.

29:25More from Bloomberg Businessweek Daily coming up after this.

29:31These days, it seems like AI agents are just about everywhere you turn, every field and every function. But without identity, you can't trust they'll serve your business instead of jeopardizing it. Fortunately, Okta helps you get identity right by securing your AI agent's identities, giving you a single layer of control, a single standard of trust. So whether an AI agent supports a single user or your entire enterprise, with Okta, you'll turn risk into opportunity. Secure every agent. Secure any agent. Okta secures AI. Support for the show comes from Public. Public is an investing platform that offers access to stocks, options, bonds, and crypto.

30:10And they've also integrated AI with tools that can assist investors in building customized portfolios. One of these tools is called Generated Assets. It allows you to turn your ideas into investable indexes. So let's say you're interested in something specific like biotech companies with high R &D spend, small cap stocks with improving operating margins, or the S &P 500 minus high debt companies. Chances are there isn't an ETF that fits your exact criteria. But on public, you just type in a prompt and their AI screens thousands of stocks and builds a one-of-a-kind index. You can even backtest it against the S &P 500.

30:46Then you can invest in a few clicks. Go to public.com slash market and earn an uncapped 1 % bonus when you transfer your portfolio. That's public.com slash market. Add paid for by Public Holdings. Brokered services by Public Investing, member FINRA SIPC. Advisory services by Public Advisors, SEC Registered Advisor, crypto services by ZeroHash. Sample prompts are for illustrative purposes only, not investment advice. All investing involves risk of loss. See complete disclosures at public.com slash disclosures. When you own your own business, you own every decision. Now own the card that rewards you for it.

31:20The Chase Sapphire Reserve for Business card brings the best Sapphire Reserve benefits to business owners who expect hardworking rewards. Designed to meet the needs of business owners at scale, this pay-in-full card elevates your travel experience and offers premium benefits and value toward business services that will take your business to the next level. Fuel your business and maximize rewards with 8x points on all purchases through Chase Travel, 3x points on social media and search engine advertising, annual partnership credits, and more. Make every journey more rewarding with a$300 annual travel credit and access to a network of airport lounges.

31:57whether you're looking for pre-flight productivity or time to rest and recharge. Chase Sapphire Reserve for Business. It's the card that gives back all you put in. Learn more at chase.com forward slash reserve business. Chase for Business. Make more of what's yours. Accounts subject to credit approval. Restrictions and limitations apply. Cards are issued by JPMorgan Chase Bank N.A., member FDIC. You're listening to the Bloomberg Business week daily podcast. Catch us live weekday afternoons from two to five Eastern. Listen on Apple CarPlay and Android Auto with the Bloomberg Business app or watch us live on YouTube.

32:34We've got David Roman with us, U.S. MedTech and healthcare IT research analyst at Goldman Sachs. He joins us from our San Francisco Bureau. Madison Muller is also here. She's Bloomberg News, U.S. healthcare reporter. She joins us here in the Bloomberg Interactive Brokers Studio. David, we wanted to get you on the program and Madison here as well, because the 47th annual Goldman Sachs Global Healthcare Conference just wrapped up in Miami last week among the themes M &A, AI, China, global policy. Would you say it's fair to say you left the conference feeling more bullish than when you arrived? Sure, Tim Carroll, Madison, thank you for having me today.

33:14Look, medical, med tech and healthcare IT has been one of the more challenging parts of healthcare this year, really, as the industry goes through a series of innovation, kind of overhaul and changes that have driven a slowdown in growth that we expect to resume in 2027. And I came out of the conference, very bullish on the scope of innovation across the space, you mentioned AI and M &A, and some of the factors that are the potential to drive growth here. And While 2026 may prove to be a more challenging year for the space, there's a lot of factors that we think have the potential to accelerate growth in 2027 and thereafter.

33:49So we know, I mean, AI is something that industries and companies across the board are talking about, our healthcare companies included. And, you know, we hear a lot about drug development and AI and various ways that these companies are implementing it. What to you right now is actually like the most promising part of AI when it comes to healthcare companies? It's a great question, Madison, because I think one of the things that everyone has struggled with is how do you take AI as a concept and turn it into a business? And you look across the med tech and healthcare IT industry, this is an area where I think you're actually seeing that happen right now.

34:21And let me give you two very specific examples of companies that I cover. One is Dexcom. A company is one of the market leaders in continuous glucose monitoring. as they look to advance the management of patients suffering from diabetes, one of the areas where AI can play a really significant role is things like carb counting. Patient can take a picture of a meal and see exactly what the predicted impact on their glucose might be. So Dexcom and Abbott, leaders in this space, and it's all about here simplification of diabetes management and automating that process for patients who do need to deliver insulin and count carbs and other metabolic factors.

34:55Second example is a technology called Zeopatch with company tickers IRTC or iRhythm. They make a product that helps physicians identify patients who may be at risk of suffering and arrhythmia. Patient wears something like this for 14 or 30 days. So just think about the vast amount of data that's being ingested there and the ability to triage that and give physicians the intel they need to make a rapid diagnostic that can lead to an intervention. and help patients in a more timely way and reduce things like unnecessary hospitalizations. Those are two of the primary examples that I would point to.

35:29And the third is around robotic surgery. Intuitive has a product called MyIntuitive Plus. It's a software platform that aggregates data across surgical procedures to help inform things like physician training and to sort of standardize and normalize these procedures, which still sit in the hands of individuals. but the extent to which you can use data to standardize utilization should drive further adoption of these technologies. Why are they so down so much? Irythm is down almost 40%. It's about a$3.5 billion market cap company. Intuitive Surgical, it's a company we often talk a lot about, down about 26 % year to date.

36:09What's going on? Yeah, there are two things at play here. One is a rotation out of medtech was one of the better performing sectors in healthcare heading into 2026 with the signing of the 17 mfn deals we really saw biopharma become very much a sector that drew drove a lot of rotation out of medtech into biotech than pharma the second is concerns around the macro environment so how things like changes to the affordable care act will impact volumes how things like medicaid changes might impact how hospitals invest in capital and you've seen, you haven't really seen anything like that play out, but the stocks have really pre-traded that and taken a very short-term view of growth, which is why we're optimistic about 2027, both from a business perspective and stock standpoint.

36:53And Intuitive probably represents one of the names that we like that is down quite a bit here, where that does have the potential to turn here as revenue growth improves throughout the year. Because you mentioned Abbott and Dexcom, I'm curious what you think of the consumer opportunity there and the consumer market, both with what you were talking about with AI, but also with continuous glucose monitors, which both companies are looking to get into more actual healthy consumers, not people with diabetes. What sort of opportunity are we looking at? It does feel like at some point we're all going to be just wearing.

37:25I mean, I know we can already certain things, but that everybody or that your health insurer is going to require you to wear something to monitor everything. But anyway, take it away off of Madison's question. Yeah, no, I mean, it's interesting that you bring that up, because one of the things that Dexcom is talking about is wearing continuous glucose monitors before you go to a physical, for example, to gather relevant data around stress, sleep, glucose, et cetera, that can better inform how a physician treats you. Remember, an average primary care physician will see 25 to 40 patients a day. So the extent to which that individual can be armed with relevant data should help them better triage patients and manage them accordingly.

38:02So the consumer opportunity on CGM specifically, I'm shocked, actually, at how fast it's gone. Dexcom generated about$100 million in revenue for their Stellar product last year. They've talked about it growing about 50 % this year. And remember, these are products that patients will use maybe a couple times a year. So the fact that you're seeing that early adoption rate suggests that there's just a massive volume of adoption. We think the whole wellness theme is really in its infancy as it relates to the intersection of healthcare and wellness. And this is where AI and technology becomes so important because information data will ultimately inform how patients manage wellness and then eventually health care.

38:41Hey, David, more on the continuous glucose monitors, but this time for in the context of people who do have diabetes. I was actually talking to a neighbor recently and he was looking at his app. He does have diabetes. And he was he said, OK, this one measures, you know, this is the device that measures my glucose. I have also the insulin pump that, you know, automatically pumps there. But he said, the problem is I don't have an app that just does both of these that's been approved by the FDA. So he was showing me this sort of like sideloaded, you know, like gray market app that he said he's been using for years.

39:13The regulatory environment, like why can't there be an app that talks to each other officially that is approved by regulators? So a lot of companies are working on something called the pump companies are working on something called closed loop therapy that would integrate insulin delivery with with pump therapy. therapy. So right now there's something called automated insulin delivery or AID. You can, in some cases, control your CGM app from the pump app. One of the dynamics here is that CGM tends to be what patients go on first and then they go on a pump. It's very rare that you see patients go on them together.

39:47So they're developed and approved separately. So that's one of the factors at play here. But there are a series of apps now, for example, on Insults app, You can access your Dexcom CGM through the pump app in some cases. So that is evolving, but you will still see them as different products. David, we want to have more time with you. You've got to come back soon and join us once again. David Roman, he's U.S. MedTech and healthcare IT research analyst at Goldman Sachs. He's out there in our San Francisco Bureau. And always a huge thank you to Madison Muller, Bloomberg News, U.S. healthcare reporter here in the Bloomberg Interactive Brokers Studio.

40:26This is the Bloomberg Business Week Daily podcast, available on Apple, Spotify, and anywhere else you get your podcasts. Listen live weekday afternoons from 2 to 5 p.m. Eastern on Bloomberg.com, the iHeartRadio app, TuneIn, and the Bloomberg Business app. You can also watch us live every weekday on YouTube and always on the Bloomberg Terminal.

40:58These days, it seems like AI agents are just about everywhere you turn, every field and every function. But without identity, you can't trust they'll serve your business instead of jeopardizing it. Fortunately, Okta helps you get identity right by securing your AI agent's identities, giving you a single layer of control, a single standard of trust. So whether an AI agent supports a single user or your entire enterprise, with Okta, you'll turn risk into opportunity. Secure every agent. Secure any agent. Okta secures AI. We learned how to love dogs from the dogs that loved us and waited for us to get home from school.

41:36They were the dogs that raised us. We returned the love with Pedigree dog food. It was good then. It's better now. For 40 years, Pedigree has been bringing out the goodness in dogs. Every bowl serves up 100 % of the nutrition your dog needs, supporting six health essentials. That's the Pedigree goodness promise. Pedigree. Good then, better now. Ask yourself, what are your best people spending their time on right now? Expense reports? Receipt chasing? Month-end close that takes weeks? You become what you spend on, and that's not what you're building toward. Brex is the intelligent finance platform that eliminates that work before it starts.

42:17AI agents that handle the manual stuff automatically, so your team can spend their time on what actually compounds. It's time to get Brex AF. Learn more at brex.com slash AF.

From the publisher

The people, companies and trends shaping the global economy. Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF.

SpaceX jumped for a third straight day on Tuesday, overtaking Amazon.com in value to become the fifth-largest stock in the world.

Shares closed 4.8% higher, pushing its market capitalization to $2.65 trillion, roughly $8 billion higher than Amazon’s. At the stock’s intraday high, the market value of Elon Musk’s rocket and AI company topped Microsoft to briefly become the world’s fourth-largest stock.

At least some of the price action since its debut has been driven by the relatively small number of SpaceX shares available to trade, with only about 4.2% accessible on day one. That can make trading more volatile, with the stock more prone to large swings that can quickly change its market value.

On this episode, Carol and Tim speak with:

  • Bailey Lipschultz, Bloomberg News IPO Reporter on SpaceX's continued rally
  • Simon White, Bloomberg Macro Strategist On The GPU Is Wall Street’s New Real Estate Trade
  • Mike Dinsdale, CEO at Powerlaw
  • David Roman, US MedTech and Healthcare IT Research Analyst, Goldman Sachs AND Madison Muller, Bloomberg News US Health Care Reporter

See omnystudio.com/listener for privacy information.

More from Bloomberg Businessweek

All 738 episodes
SpaceX Rallies For Third Straight Day, Becoming World's Fifth Largest StockBloomberg Businessweek · 35 min
Listen in VO